Mathe Melchisedec Kirere, Lepage Philippe
Institut supérieur des techniques médicales, Centre médical évangélique de Nyankunde (en RDC), 104, Rue En-Bois, 4000 Liège, Belgique.
Sante. 2007 Apr-Jun;17(2):97-101.
Several developing countries, including the Democratic Republic of the Congo have adopted HIV NET 012, i.e. a single dose of nevirapine to mother (200 mg at labour onset) and baby (2 mg/kg within 72 h of birth), because of the accessible cost of nevirapine and its supposedly easy use in MTCTP programs [2]. The protocol can nonetheless prove complex to apply in rural regions of Africa and must be evaluated. This article aims to present the difficulties encountered in implementation of this protocol at the Oicha General Reference Hospital, in the northeastern region of the Democratic Republic of the Congo. The study took place time from December 2002 through December 2004. During the study period, 94 women were identified as HIV positive at the prenatal clinic of Oicha Hospital. Of the 94 HIV positive women: 59 (62.8%) received antiretroviral prophylaxis and 35 (37.2%) did not receive nevirapine despite their identification at the prenatal clinic. Among these 35 women, 26 (27.7%) of the expected women arrived fully dilated and thus went directly to the delivery room. Nine (9.5%) of the expected women who delivered at the Oicha maternity were not administered the product by the midwives. For administration of nevirapine to the mother: 33 pregnant women out of 59 (55.9%) received nevirapine within the time recommended - within two hours of the onset of contractions. Twenty four of 59 women (40.7%) did not receive the nevirapine within the time recommended, but within an average delay of 11.00 hours. For 2 of 59 women (3.4%), the hour of administration of the nevirapine was not specified. For administration of nevirapine to the child: 48 of 101 children (47.5%) received nevirapine within the recommended period, i.e. in the 24-72 hours after birth. 52 of 101 children (51.5%) received the nevirapine in an average of 2.9 hours of birth. This is the proportion of the children whose mothers arrived at the maternity ward ready for delivery. Only 1 child (1%) received the nevirapine later than the recommended period, 13.9 hours later. Applying as simple a protocol as the HIV prophylaxis program with nevirapine in African rural areas encounters difficulties.
包括刚果民主共和国在内的几个发展中国家已经采用了HIV NET 012方案,即给母亲单剂量奈韦拉平(分娩开始时200毫克)和婴儿(出生后72小时内2毫克/千克),这是因为奈韦拉平成本可及且据称在预防母婴传播项目中易于使用[2]。然而,该方案在非洲农村地区实施起来可能很复杂,必须进行评估。本文旨在介绍在刚果民主共和国东北部地区的奥伊查综合参考医院实施该方案时遇到的困难。该研究于2002年12月至2004年12月期间进行。在研究期间,奥伊查医院产前诊所确认94名妇女为HIV阳性。在这94名HIV阳性妇女中:59名(62.8%)接受了抗逆转录病毒药物预防,35名(37.2%)尽管在产前诊所被确认,但未接受奈韦拉平。在这35名妇女中,26名(27.7%)预期分娩的妇女宫口全开,因此直接进入产房。在奥伊查妇产科分娩的9名(9.5%)预期妇女未由助产士给予该药物。对于给母亲使用奈韦拉平:59名孕妇中有33名(55.9%)在推荐时间内——宫缩开始后两小时内——接受了奈韦拉平。59名妇女中有24名(40.7%)未在推荐时间内接受奈韦拉平,但平均延迟了11.00小时。59名妇女中有2名(3.4%),奈韦拉平的给药时间未注明。对于给儿童使用奈韦拉平:101名儿童中有48名(47.5%)在推荐期间内,即出生后24至72小时内接受了奈韦拉平。101名儿童中有52名(51.5%)平均在出生后2.9小时接受了奈韦拉平。这是其母亲抵达产科病房准备分娩的儿童比例。只有1名儿童(1%)在推荐时间之后,即13.9小时后接受了奈韦拉平。在非洲农村地区应用像使用奈韦拉平进行HIV预防项目这样简单的方案也会遇到困难。